Frontiers in Immunology (Jan 2023)
Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination
- Takuto Nogimori,
- Takuto Nogimori,
- Koichiro Suzuki,
- Yuji Masuta,
- Yuji Masuta,
- Ayaka Washizaki,
- Ayaka Washizaki,
- Mika Yagoto,
- Mami Ikeda,
- Yuki Katayama,
- Hidenori Kanda,
- Minoru Takada,
- Shohei Minami,
- Takeshi Kobayashi,
- Shokichi Takahama,
- Shokichi Takahama,
- Yasuo Yoshioka,
- Yasuo Yoshioka,
- Yasuo Yoshioka,
- Yasuo Yoshioka,
- Takuya Yamamoto,
- Takuya Yamamoto,
- Takuya Yamamoto,
- Takuya Yamamoto,
- Takuya Yamamoto
Affiliations
- Takuto Nogimori
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Takuto Nogimori
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Koichiro Suzuki
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, Japan
- Yuji Masuta
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Yuji Masuta
- Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Ayaka Washizaki
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Ayaka Washizaki
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Mika Yagoto
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Mami Ikeda
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Yuki Katayama
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Hidenori Kanda
- KINSHUKAI, Hanwa Memorial Hospital, Osaka, Japan
- Minoru Takada
- KINSHUKAI, Hanwa The Second Senboku Hospital, Osaka, Japan
- Shohei Minami
- Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Takeshi Kobayashi
- Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Shokichi Takahama
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Shokichi Takahama
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Yasuo Yoshioka
- The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, Japan
- Yasuo Yoshioka
- Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Yasuo Yoshioka
- Laboratory of Nano-design for innovative drug development, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Yasuo Yoshioka
- 0Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan
- Takuya Yamamoto
- Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
- Takuya Yamamoto
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Takuya Yamamoto
- Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Takuya Yamamoto
- Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
- Takuya Yamamoto
- 1Department of Virology and Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan
- DOI
- https://doi.org/10.3389/fimmu.2022.1081047
- Journal volume & issue
-
Vol. 13
Abstract
Understanding the T-cell responses involved in inhibiting COVID-19 severity is crucial for developing new therapeutic and vaccine strategies. Here, we characterized SARS-CoV-2 spike-specific CD8+ T cells in vaccinees longitudinally. The BNT162b2 mRNA vaccine can induce spike-specific CD8+ T cells cross-reacting to BA.1, whereas the T-cell receptor (TCR) repertoire usages decreased with time. Furthermore the mRNA vaccine induced spike-specific CD8+ T cells subpopulation expressing Granzyme A (GZMA), Granzyme B (GZMB) and Perforin simultaneously in healthy donors at 4 weeks after the second vaccination. The induced subpopulation was not maintained at 12 weeks after the second vaccination. Incorporating factors that efficiently induce CD8+ T cells with highly cytotoxic activity could improve future vaccine efficacy against such variants.
Keywords
